Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has granted stock options to one new employee. The compensation committee approved non-qualified stock options to purchase 48,000 shares of common stock on September 24, 2025.
The stock options will vest quarterly over four years, with 1/16 of the shares vesting each quarter, contingent on continued employment. The grant was made under Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023, and complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement grant.
Biomea Fusion (Nasdaq: BMEA), azienda clinicamente impegnata nello sviluppo di farmaci per il diabete e l'obesità, ha assegnato stock option a un nuovo dipendente. Il comitato di compensazione ha approvato stock option non qualificate per l'acquisto di 48.000 azioni ordinarie in data 24 settembre 2025.
Le stock option matureranno trimestralmente nel corso di quattro anni, con 1/16 delle azioni che si VESTIRANNO ogni trimestre, soggette al mantenimento dell'impiego. La concessione è stata effettuata ai sensi del Piano di Induzione Azionaria 2023 di Biomea, adottato il 17 novembre 2023, e rispetta la Nasdaq Listing Rule 5635(c)(4) come concessione di indizione all'occupazione.
Biomea Fusion (Nasdaq: BMEA), una empresa en etapa clínica de medicamentos para la diabetes y la obesidad, ha otorgado opciones sobre acciones a un nuevo empleado. El comité de compensación aprobó opciones no calificadas para comprar 48.000 acciones comunes el 24 de septiembre de 2025.
Las opciones se consolidarán de forma trimestral durante cuatro años, con 1/16 de las acciones vestidas cada trimestre, sujeto a la continuidad en el empleo. La concesión se realizó bajo el Plan de Inducción de Acciones 2023 de Biomea, aprobado el 17 de noviembre de 2023, y cumple con la Nasdaq Listing Rule 5635(c)(4) como otorgamiento por inducción de empleo.
Biomea Fusion (나스닥: BMEA), 임상 단계의 당뇨 및 비만 치료제 회사가 새로운 직원에게 주식매수선택권을 부여했습니다. 보상 위원회는 2025년 9월 24일 48,000주의 보통주를 매수할 수 있는 비자격 주식매수선택권을 승인했습니다.
이 옵션은 4년에 걸쳐 분기별로 vest되며, 매 분기 1/16의 주식이 vest됩니다. 고용 지속 여부에 따라 달라집니다. 이번 부여는 Biomea의 2023 Inducement Equity Plan에 따라 이루어졌으며, 2023년 11월 17일 채택되었고 Nasdaq Listing Rule 5635(c)(4)를 고용 유인 부여로 준수합니다.
Biomea Fusion (Nasdaq : BMEA), entreprise pharmaceutique clinique spécialisée dans le diabète et l’obésité, a accordé des options d’achat d’actions à un nouvel employé. Le comité de rémunération a approuvé des options d’achat non qualifiées pour 48 000 actions ordinaires le 24 septembre 2025.
Ces options se vestent trimestriellement sur une période de quatre ans, avec 1/16 des actions qui se vestent à chaque trimestre, sous condition de maintien de l’emploi. Cette attribution a été effectuée dans le cadre du Plan d’action d’induction 2023 de Biomea, adopté le 17 novembre 2023, et est conforme à la règle Nasdaq Listing 5635(c)(4) en tant que attribution d’induction à l’emploi.
Biomea Fusion (Nasdaq: BMEA), ein klinisch orientiertes Unternehmen für Diabetes- und Fettleibigkeitsmedikamente, hat einem neuen Mitarbeiter Optionsscheine gewährt. Der Vergütungsausschuss genehmigte 48.000 Stammaktien in Form von Nicht-Qualifizierten Aktienoptionen am 24. September 2025.
Die Optionen werden quartalsweise über vier Jahre vesten, wobei jeweils 1/16 der Aktien pro Quartal vesten, abhängig von der fortgesetzten Beschäftigung. Die Zuteilung erfolgte im Rahmen des 2023 Inducement Equity Plan von Biomea, der am 17. November 2023 verabschiedet wurde, und entspricht der Nasdaq Listing Rule 5635(c)(4) als Beschäftigungsanreiz-Zuteilung.
Biomea Fusion (ناسداك: BMEA)، شركة أدوية قيد التطوير لعلاج الداء السكري والسمنة، قد منحت خيارات أسهم لموظف جديد. وافق لجنة التعويض على خيارات أسهم غير مؤهلة لشراء 48,000 سهم من الأسهم العادية في 24 سبتمبر 2025.
ستترسخ هذه الخيارات ربع سنويًا على مدى أربعة أعوام، مع vesting لكل ربع سنة بمعدل 1/16 من الأسهم، رهناً باستمرار العمل. جاءت المنحة في إطار خطة حوافز الأسهم 2023 لدى Biomea، التي اعتمدت في 17 نوفمبر 2023، وتلتزم بقاعدة Nasdaq Listing 5635(c)(4) كمنحة حافز توظيف.
Biomea Fusion (纳斯达克股票代码：BMEA)，一家处于临床阶段的糖尿病与肥胖药物公司，已向一名新员工授予股票期权。薪酬委员会已于2025年9月24日批准非合格购买普通股的股票期权，数量为48,000 股。
这些股票期权将在
- None.
- None.
SAN CARLOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on September 24, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase 48,000 shares of the Company’s common stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to such employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).
The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.
About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com
FAQ
What stock options did Biomea Fusion (BMEA) grant to its new employee?
How will the stock options vest for the new Biomea Fusion employee?
What is Biomea Fusion's (BMEA) 2023 Inducement Equity Plan?
What type of company is Biomea Fusion (BMEA)?
